This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Catherine Sohn Elected To Jazz Pharmaceuticals Board Of Directors





DUBLIN, July 30, 2012 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the election of Catherine Angell Sohn, Pharm.D., CLP, to its board of directors at the company's annual meeting of shareholders held on July 27, 2012.

"Cathy has extensive product and business development experience and brings a strong patient-focused perspective to our board," said Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals.  "As we strengthen our operations in both the United States and Europe, continue to optimize our commercial activities and evaluate product development strategies for the future, Cathy will add tremendous value."

Catherine Angell Sohn, Pharm.D., CLP, is the founder of Sohn Health Strategies where she consults for pharmaceutical, biotechnology, medical device, and consumer healthcare companies in the areas of business strategy, business development and strategic product development. She currently serves on the boards of Ariel Pharmaceuticals, Inc., a privately held specialty pharmaceutical company, and The Dohmen Company, a privately held provider of business services to life science companies. She also serves on the Dean's Advisory Council for Drexel University School of Public Health, the Ben Franklin Technology Partners Investment Advisory Committee, Ernst & Young's global Life Science Advisory Board, Springboard Enterprises Life Science Council and the global advisory board of the Healthcare Businesswomen's Association. 

From 1982 to 2010, Dr. Sohn was with GlaxoSmithKline plc (and with SmithKline Beecham plc before its merger with GlaxoWellcome plc), where she served most recently as senior vice president, worldwide business development and strategic alliances in the GSK Consumer Healthcare division.  Previously, she held a series of positions in medical affairs, pharmaceutical business development, U.S. product marketing, and global strategic product development in the pharmaceutical division.  She also previously served on the boards of multiple non-profit organizations, including two terms on the Health Advisory Board for the Johns Hopkins University Bloomberg School of Public Health and as vice chair of the Corporate Executive Board of the Philadelphia Museum of Art.

Dr. Sohn started her career as Assistant Professor of Clinical Pharmacy at the University of the Sciences in Philadelphia, where she currently holds the position of Dean's Professor. She received a Pharm.D. from the University of California, San Francisco, School of Pharmacy. She also received a Certificate of Professional Development from The Wharton School at the University of Pennsylvania.

About Jazz Pharmaceuticals Jazz Pharmaceuticals plc is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing products that address unmet medical needs. The company has a diverse portfolio of products in the areas of narcolepsy, oncology, pain, psychiatry and women's health. The company's U.S. marketed products in these areas include: Xyrem ® (sodium oxybate), Erwinaze™ (asparaginase  Erwinia chrysanthemi), Prialt ® (ziconotide intrathecal infusion), FazaClo ® (clozapine USP) HD and LD, Luvox CR ® (fluvoxamine maleate) and Elestrin ® (estradiol gel 0.06%). Outside of the U.S., Jazz Pharmaceuticals also has a number of products marketed by an international division, EUSA Pharma.

SOURCE Jazz Pharmaceuticals plc

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,982.59 +22.02 0.13%
S&P 500 1,978.91 +0.57 0.03%
NASDAQ 4,444.9090 -4.6550 -0.10%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs